AstraZeneca's Cancer Drug Trial Disappoints, Sending Shares Lower - New York Times

New York Times

AstraZeneca's Cancer Drug Trial Disappoints, Sending Shares Lower New York Times AstraZeneca also announced on Thursday that it would collaborate with Merck on developing Lynparza, a drug for various types of tumors, including breast, prostate and pancreatic cancers, and selumetinib, a drug that could be used on thyroid cancer. AstraZeneca results in line as new partnership struck with Merck, Mystic disappointsDIGITALLOOK all 80 news articles »

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2eRaW3Y
via IFTTT